Arrowhead rises as U.S. FDA grants breakthrough tag for rare blood fat disorder drug

Arrowhead Pharmaceuticals

02/12/2025 14:01

** Shares of drug developer Arrowhead Pharmaceuticals  ARWR.O rise 1% to $57.23 premarket

** Co says U.S. FDA  grants breakthrough tag to its experimental drug plozasiran for treating patients with severe hypertriglyceridemia

** Hypertriglyceridemia involves very high blood fat levels, raising risk of acute pancreatitis

** Co's plozasiran aims to lower blood fats by blocking apoC-III, a protein that slows fat breakdown - ARWR

** ARWR plans to finish late-stage trials by mid-2026

** Co expects to file for FDA approval by end-2026 and seek global clearances later

** Up to last close, stock up ~199%

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))